Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according to PitchBook. “In 2025, venture capitalists are expected to prioritize ...
With what Insmed calls an "outstanding" phase 2 win for its treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH), the company is racing to phase 3 as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback